Carol Gallagher, Pharm.D., is a Partner at NEA (New Enterprise Associates) and also currently serves on the Boards of Atara Bio, Cleave Biosciences, and Millendo. She previously served as a Director of Aragon Pharmaceuticals prior to the company’s acquisition by Johnson and Johnson in 2013. Dr. Gallagher has served in various commercial and drug development operational roles in both large and small biopharmaceutical companies. Her most recent operational role was the CEO of Calistoga Pharmaceuticals, where she led a team experienced leaders in developing CAL-101, now called ZYDELIG®. Calistoga Pharmaceuticals was acquired by Gilead Sciences in 2011.